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ORIGINAL RESEARCH ARTICLE

Editorial, see p 2322
BACKGROUND: Endovascular treatment with mechanical thrombectomy (MT)
is beneficial for patients with acute stroke suffering a large-vessel occlusion,
although treatment efficacy is highly time-dependent. We hypothesized that
interhospital transfer to endovascular-capable centers would result in treatment
delays and worse clinical outcomes compared with direct presentation.
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METHODS: STRATIS (Systematic Evaluation of Patients Treated With
Neurothrombectomy Devices for Acute Ischemic Stroke) was a prospective,
multicenter, observational, single-arm study of real-world MT for acute stroke
because of anterior-circulation large-vessel occlusion performed at 55 sites over
2 years, including 1000 patients with severe stroke and treated within 8 hours.
Patients underwent MT with or without intravenous tissue plasminogen activator
and were admitted to endovascular-capable centers via either interhospital transfer
or direct presentation. The primary clinical outcome was functional independence
(modified Rankin Score 0–2) at 90 days. We assessed (1) real-world time metrics of
stroke care delivery, (2) outcome differences between direct and transfer patients
undergoing MT, and (3) the potential impact of local hospital bypass.
RESULTS: A total of 984 patients were analyzed. Median onset-to-revascularization
time was 202.0 minutes for direct versus 311.5 minutes for transfer patients
(P<0.001). Clinical outcomes were better in the direct group, with 60.0%
(299/498) achieving functional independence compared with 52.2% (213/408) in
the transfer group (odds ratio, 1.38; 95% confidence interval, 1.06–1.79; P=0.02).
Likewise, excellent outcome (modified Rankin Score 0–1) was achieved in 47.4%
(236/498) of direct patients versus 38.0% (155/408) of transfer patients (odds
ratio, 1.47; 95% confidence interval, 1.13–1.92; P=0.005). Mortality did not differ
between the 2 groups (15.1% for direct, 13.7% for transfer; P=0.55). Intravenous
tissue plasminogen activator did not impact outcomes. Hypothetical bypass
modeling for all transferred patients suggested that intravenous tissue plasminogen
activator would be delayed by 12 minutes, but MT would be performed 91 minutes
sooner if patients were routed directly to endovascular-capable centers. If bypass
is limited to a 20-mile radius from onset, then intravenous tissue plasminogen
activator would be delayed by 7 minutes and MT performed 94 minutes earlier.
CONCLUSIONS: In this large, real-world study, interhospital transfer was associated
with significant treatment delays and lower chance of good outcome. Strategies
to facilitate more rapid identification of large-vessel occlusion and direct routing to
endovascular-capable centers for patients with severe stroke may improve outcomes.
CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique
identifier: NCT02239640.
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Clinical Perspective
What Is New?
• This large real-world study shows that patients
who are transferred between hospitals for endovascular stroke treatment have worse outcomes
compared with those who presented directly to an
endovascular-capable center.
• Delays to endovascular treatment account for the
difference in outcomes between direct and transfer
patients.
• A hypothetical bypass analysis showed that if
patients were brought directly to the endovascularcapable center, tissue plasminogen activator would
be slightly delayed by 12 minutes, but endovascular
treatment would be delivered 91 minutes sooner.
• If limited to bypass of <20 miles, tissue plasminogen
activator is delayed by only 7 minutes, but endovascular treatment is delivered 94 minutes sooner.

What Are the Clinical Implications?
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• These findings reinforce that early recanalization
leads to better outcomes. Stroke systems of care
should be optimized to get patients to appropriate
treatment quickly.
• When possible, interhospital transfer should be
avoided.
• Our hypothetical bypass analysis showed that
transporting patients directly to endovascularcapable facilities has only a modest impact on timing of intravenous tissue plasminogen activator
delivery but can have a significant reduction in time
to endovascular recanalization.
• This finding was especially true for bypass distances
of <20 miles.
• Thus, bypass to the nearest endovascular-capable
stroke center should be strongly considered if it is
within 20 miles.

I

schemic stroke is the leading cause of disability in the
United States, and the burden of stroke continues to
increase worldwide.1,2 Acute large-vessel occlusion
(LVO) causes some of the largest and most disabling
strokes.3 Fortunately, multiple recent trials have shown
that endovascular mechanical thrombectomy (MT) leads
to significantly better outcomes in patients with LVO
stroke compared with medical therapy alone.4–8 STRATIS
(Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke) was a
prospective, multicenter, observational, single-arm registry of patients with LVO stroke treated with MT, which
showed that outcomes similar to those observed in clinical trials can be achieved in a real-world setting.9
The strongly positive effect of MT in acute stroke is
highly time-dependent. A recent patient-level metaanalysis of MT for LVO showed that the benefit associ2312
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ated with MT decreases with each 1-hour delay to treatment, and that benefit became nonsignificant after 7.3
hours from stroke onset.10 Thus, achieving timely treatment is critically important to realize the benefits of MT.
This timeliness is highly dependent on the entire system
of care, including prehospital triage and routing. Many
patients with acute stroke are transported to the nearest hospital, which is often not capable of endovascular
treatment. In these cases, patients undergo a rapid diagnostic workup, and may receive intravenous tissue-type
plasminogen activator (IV-tPA) at the community hospital before being transferred to an endovascular-capable
center. We hypothesized that such transfers might be
associated with additional treatment delays and consequent reduction in likelihood of good clinical outcome.

METHODS
Study Design and Inclusion Criteria
STRATIS was a prospective, multicenter, observational registry
evaluating the use of Medtronic market-released MT devices
in consecutive patients with acute ischemic stroke because
of LVO in the anterior circulation between August 2014 and
June 2016 from 55 sites (see Table I in the online-only Data
Supplement for individual site characteristics) with approval
from local institutional review boards. Patients were enrolled
from the time of arrival at the enrolling hospital up to the
day of hospital discharge, or ≤7 days after MT. Enrollment
was planned to include ≤1000 patients to create the largest
registry of patients with LVO stroke to date.
The inclusion criteria were (1) informed consent before
enrollment in the registry, (2) acute stroke because of LVO
that had been or would be treated with a Medtronic marketreleased MT device as the initial device, (3) treatment within
8 hours of stroke onset, (4) prestroke modified Rankin Scale
(mRS) score of ≤2, and (5) pretreatment National Institutes of
Health Stroke Scale (NIHSS) score of ≥8 and ≤30 as reported
by the enrolling center. The qualifying NIHSS could be collected at either the initial or enrolling hospital, and there
was no requirement that it be repeated before MT. Use of
a Medtronic MT device and enrollment in the registry were
at the discretion of the site clinician-investigator; patients
treated with other devices were not included in the registry.

Outcomes
The primary outcome was functional status as assessed by
mRS at 90 days performed by the local treatment team, either
in person or by telephone, and verification of assessor certification was not verified. Clinical end points were defined as
follows: mRS 0 to 2 = functional independence, and mRS 0 to
1 = excellent clinical outcome. Total stroke onset-to-revascularization time was a secondary end point. Revascularization
was defined as modified Thombolysis in Cerebral Ischemia
2b or 3, corresponding to substantial or complete reperfusion, and was determined by an independent core imaging
laboratory. Only patients achieving successful revascularization were included in time analyses. Patients were compared
between 2 groups: those who presented directly to the
endovascular-capable hospital (direct) versus patients who
Circulation. 2017;136:2311–2321. DOI: 10.1161/CIRCULATIONAHA.117.028920
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To reduce delays to MT, some have proposed direct emergency
medical services routing to endovascular-capable centers.12–14
To evaluate the potential impact of such a strategy, we performed hypothetical bypass modeling for patients who had
been brought by emergency medical services first to a nonendovascular hospital and then transferred by ground ambulance
to the endovascular-capable center (air transfer patients were
excluded because the distances can be farther and ground
velocity could not be predicted). The projected direct-to-endovascular-capable hospital (bypass) time was calculated based
on the actual driving distance from the scene directly to the
endovascular-capable center combined with the actual average ambulance velocity observed during the interfacility transport and a projected average emergency medical services time
on scene of 15 minutes.15–17 For patients with IV-tPA, the average (mean) door–to–tissue-type plasminogen activator (tPA)
time at endovascular-capable sites was then added to predict onset-to-tPA time. Any patients whose predicted bypass
onset-to-tPA time exceeded guideline recommendations15
were identified as no longer tPA-eligible. Finally, average doorto-puncture time was added to yield total bypass-projected
treatment time. This analysis was repeated for patients initially
within 20 miles of the endovascular-capable center because
nearer bypasses may be more plausible.

Statistical Analysis
Standard descriptive statistics were used, including mean,
SD, and median with interquartile range (IQR) for continuous variables and frequency distributions for categorical variables. For between-group comparisons, t tests and Wilcoxon’s
rank sum were used for continuous variables, and χ2 tests
and Fisher exact tests was used for categorical variables. Twotailed P values <0.05 were considered statistically significant.
Statistical analyses were conducted in SAS version 9.2 or
above (SAS Institute) and R version 3.2 or above (R Foundation
for Statistical Computing). Outcome variables (mRS) were
modeled against predictors of interest using logistic regression adjusted for age, qualifying NIHSS, occlusion location,
use of tPA, transfer status, and time from onset. In this model,
age, NIHSS, and time from onset were regarded as continuous predictors, whereas occlusion location, tPA, and transfer
status were categorical. Time from onset, as the continuous
Circulation. 2017;136:2311–2321. DOI: 10.1161/CIRCULATIONAHA.117.028920

predictor of principal interest, was also evaluated using a
quadratic term in the regression. Confidence intervals (CIs)
for odds ratios (ORs) were derived from these models using
normal approximation based on standard errors, whereas
predicted probabilities from the same models are presented
in graphical format. The distribution of mRS between groups
was compared using the Mantel-Haenszel ordinal χ2 statistic.
Additionally, as a sensitivity analysis, propensity scores
were constructed with transfer status as the object of propensity scoring and age, qualifying NIHSS, vessel of target
occlusion, tPA administration, ASPECTS score at baseline, sex,
arterial occlusion location, smoking status, history of atrial
fibrillation, diabetes mellitus, history of recent stroke, carotid
artery stenosis, history of coronary disease, hyperlipidemia,
prestroke functional status, and hypertension as predictors.
These covariates reflect all the variables analyzed in the recent
randomized trials of endovascular treatment for stroke4–8 and
the subsequent meta-analyses.18,19 The model for outcome
(functional independence, mRS 0–2) was then constructed
using transfer status, time from onset to arterial puncture,
and propensity as predictors in 2 fashions: by using the propensity score as a covariate in the model, and by stratification
into 5 groups based on propensity scores as per Rosenbaum
and Rubin.20

RESULTS
A total of 1000 patients were enrolled over 22 months,
but 16 did not meet the inclusion criteria (5 had baseline
mRS>2, 4 were treated beyond 8 hours, 2 consented
outside the enrollment window, 2 were without LVO, 1
lacked documentation of consent, 1 had an NIHSS<8,
and 1 had missing data), leaving 984 patients available
for analysis. Direct presentation to the endovascularcapable site was observed in 539 patients, and the
remaining 445 were transferred from another hospital to the endovascular-capable hospital for treatment.
Baseline characteristics were mostly similar between
these 2 groups (Table 1), with predictable differences in
mean initial NIHSS score (18.0±5.5 for transfers versus
16.7±5.5 for direct; P=0.0006) and ASPECTS score by
core laboratory assessment (7.9±1.8 for transfers versus
8.4±1.4 for direct; P<0.0001). IV-tPA was administered
to 628 patients: 329/539 (61.0%) of direct patients and
299/445 (67.2%) of transferred patients (P=0.044).

Time Metrics
Median onset-to-revascularization time was 202.0 minutes (IQR, 160–265) in the direct group compared with
311.5 minutes (IQR, 255–386) in the transfer group
(P<0.001), with a difference between the mean times of
100 minutes. The mean alarm-to-revascularization time,
measuring system efficiency defined as time of 911
call to treatment reperfusion, differed by 116 minutes.
Among patients who received tPA, median onset-torevascularization time was 192.0 minutes (IQR, 156–239)
for the direct group compared with 311.5 minutes (IQR,
December 12, 2017
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came by interhospital transfer to the endovascular-capable
hospital (transfer) and were additionally categorized as having received IV-tPA before MT or undergoing MT alone. The
impacts of time to treatment, direct presentation versus
transfer, and IV-tPA were assessed with a multivariate logistic
regression accounting for other covariates. For analyses of
outcome and time, the onset-to-puncture time epoch was
used rather than time to revascularization so that all patients
were included. Mortality rates at 90 days were also compared
between direct and transfer groups. Early ischemic changes
on the initial noncontrast head computed tomography were
quantified using the ASPECTS score (Alberta Stroke Program
Early CT Score), a validated measure of ischemic changes correlating with clinical outcome.11 All imaging was evaluated
by a core laboratory (University of California, Los Angeles
Neurovascular Imaging Research Core).

Froehler et al

Table 1. Baseline and Clinical Characteristics According to Admission Status
Characteristics
Patients, no.

All

Transfer

Direct

P Value

984

445

539

Age, mean (SD), y

67.8 (14.7)

66.9 (14.6)

68.5 (14.8)

0.10

Male sex, no. (%)

533 (54.2)

245 (55.1)

288 (53.4)

0.61

 Atrial flutter/atrial fibrillation

369 (37.5)

165 (37.1)

204 (37.8)

0.80

 Systemic hypertension

712 (72.4)

321 (72.1)

391 (72.5)

0.89

 Diabetes mellitus

252 (25.6)

108 (24.3)

144 (26.7)

0.38

 Myocardial disease/coronary artery disease

269 (27.3)

121 (27.2)

148 (27.5)

0.93

 Hyperlipidemia

414 (42.1)

184 (41.3)

230 (42.7)

0.68

 Peripheral artery disease

37 (3.8)

14 (3.1)

23 (4.3)

0.36

 Carotid artery disease

77 (7.8)

39 (8.8)

38 (7.1)

0.32

465 (47.3)

222 (49.9)

243 (45.1)

0.13

 ICA

223 (22.7)

100 (22.5)

123 (22.8)

0.31

 M1

541 (55.0)

250 (56.2)

291 (54.0)

M2

172 (17.5)

69 (15.5)

103 (19.1)

 Other

48 (4.9)

26 (5.8)

22 (4.1)

Medical history, no. (%)

 Current or former tobacco use
Occlusion location

Clinical characteristics
Prestroke mRS, no. (%)*

0.16

 0

748 (76.0)

326 (73.3)

422 (78.3)

 1

209 (21.2)

104 (23.4)

105 (19.5)

 2

27 (2.7)

15 (3.4)

12 (2.2)
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Initial qualifying NIHSS score, mean (SD), median (IQR)† 17.3 (5.5), 17.0 (13–22)
Treatment with IV-tPA, no. (%)
Baseline ASPECTS—per imaging core laboratory‡§
Mean (SD), median (IQR)
Successful reperfusion (mTICI 2b-3)—per imaging core
laboratory‖
No. (%)

628 (63.8)

18.0 (5.5), 18.0 (13–22)

16.7 (5.5), 17.0 (12–21)

299 (67.2)

329 (61.0)

N=763

N=306

N=457

8.2 (1.6), 8.0 (8–9)

7.9 (1.8), 8.0 (7–9)

8.4 (1.4), 9.0 (8–9)

N=824

N=356

N=468

724 (87.9)

312 (87.6)

412 (88.0)

<0.001
0.044
<0.001

0.91

ASPECTS indicates Alberta Stroke Program Early Computed Tomography Score; CT, computed tomography; ICA, internal carotid artery; IQR, interquartile
range; IV-tPA, intravenous tissue plasminogen activator (alteplase); M1, first segment of middle cerebral artery; M2, second segment of middle cerebral
artery; mRS, modified Rankin Scale; mTICI 2b-3, modified treatment in cerebral ischemia; NIHSS, National Institutes of Health Stroke Scale.
*The mRS ranges from 0 to 6, with higher scores indicating greater degree of disability.
†NIHSS ranges from 0 to 42, with higher scores indicating more severe neurological deficits.
‡ASPECTS ranges from 0 to 10, with higher scores indicating a smaller infarct core.
§Baseline imaging received for 835 patients, of whom 72 were not evaluated for ASPECTS (38 posterior stroke, 30 no noncontract CT, 4 not evaluable);
763 patients were evaluable for ASPECTS.
‖Angiograms received for 846 patients, of whom 22 were not evaluable for reperfusion status.

257–381) for the transferred group (P<0.001). A comparison of mean times yields a difference of 124 minutes
between the 2 groups, which was primarily related to
longer door-to-tPA times at nonenrolling hospitals (median, 54.5 versus 37.0, P<0.001), delays between IV-tPA
and departure from the initial hospital (median, 47 minutes; IQR, 27–85), and length of transport time (median,
35 minutes; IQR, 21–58) (Figure 1A). Similarly among
MT-alone patients, median onset-to-revascularization
time was 229.0 minutes (IQR, 175–363) for the direct
group compared with 311.5 minutes (IQR, 247–401) for
the transferred group (P<0.001), which was primarily

related to the delay between imaging completion and
departure from the transferring hospital (median, 75
minutes; IQR, 55–116) plus the length of transport time
(median, 35 minutes; IQR, 23–50) (Figure 1B).
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Clinical Outcomes
Clinical outcomes at 90 days were better in the direct
group, with 60.0% (299/498) achieving functional independence (mRS 0–2) compared with 52.2% (213/408)
in the transfer group (unadjusted OR, 1.38; 95% CI,
1.06–1.79; P=0.02) (Figure 2A). Likewise, excellent out-

Interhospital Transfer Before Thrombectomy
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Figure 1. Median time intervals
from stroke onset (the time of
last seen well) through revascularization.
A, All patients who received IV-tPA
before MT. There is a significant difference in onset-to-revascularization
times (blue line). B, All patients who
underwent MT alone (no IV-tPA).
There is a significant difference in
onset-to-revascularization times (blue
line). EMS indicates emergency medical services; IV-tPA, intravenous tissue
plasminogen activator; and MT,
mechanical thrombectomy.
Downloaded from http://ahajournals.org by on February 4, 2021

come of mRS 0 or 1 was achieved in 47.4% (236/498)
of direct patients versus 38.0% (155/408) of transfer patients (OR, 1.47; 95% CI, 1.13–1.92; P=0.005).
Comparing overall outcome by mRS shift analysis also
favored direct presentation (P=0.012 by Cochran-Mantel-Haenszel test). Mortality did not differ between the 2
groups (15.0% for direct, 13.7% for transfer; P=0.56).
Among patients who received IV-tPA before MT,
outcomes at 90 days were better in the direct group,
with 62.1% (190/306) achieving mRS 0 to 2 compared
with 53.5% (146/273) in the transfer group (OR, 1.42;
95% CI, 1.02–1.98; P=0.036) (Figure 2B). Excellent
outcomes (mRS 0–1) for patients who received IV-tPA
before MT were also observed more frequently in the
direct group compared with the transfer group (48.7%
Circulation. 2017;136:2311–2321. DOI: 10.1161/CIRCULATIONAHA.117.028920

versus 39.9%; OR, 1.43; 95% CI, 1.03–1.99; P=0.04).
In the MT-alone group, functional independence was
more common in the direct group (56.8%; 109/192)
versus the transfer group (50.0%; 67/134), although
this difference was not statistically significant (P=0.23)
(Figure 2B). For MT alone, excellent outcomes (mRS
0–1) were also observed more frequently in the direct
group compared with the transfer group (45.3% versus 34.3%; OR, 1.59; 95% CI, 1.00–2.50; P=0.047).
Comparison of outcomes by mRS shift analysis revealed
a significant difference between transfer and direct
groups for MT alone (P=0.035) and a nonsignificant
trend for IV-tPA (P=0.14).
To determine the effect on outcome attributable to
delay in time to treatment, multivariate logistic regresDecember 12, 2017
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Table 2. Effect on Good Functional Outcome
Attributable to Delay in Time to Treatment
Effect on Functional
Independence:
Odds Ratio (95% CI)

P Value

Age (per 10 y)

0.78 (0.71–0.87)

<0.001

Qualifying NIHSS (per 5 points)

0.66 (0.58–0.76)

<0.001

0.57 (0.41–0.81)

0.002

0.86 (0.58–1.27)

0.455

1.00 (NA)

NA

IV-tPA delivered (vs. mechanical
thrombectomy alone)

1.04 (0.77–1.41)

0.809

Direct admit (vs. transfer)

1.05 (0.76–1.45)

0.767

Time: onset to puncture
(per 30 min)

0.93 (0.89–0.98)

0.008

Predictor

Location of intracranial target occlusion
Internal carotid artery
 Middle cerebral artery–second
segment (M2)
 Middle cerebral artery–first
segment (M1) (reference)

CI indicates confidence interval; IV-tPA, intravenous tissue plasminogen
activator (alteplase); NA, not applicable; and NIHSS, National Institutes of
Health Stroke Scale.
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Figure 2. Unadjusted clinical outcomes at 90 days
based on mRS, presented as percentage of the total.
A, All patients, divided by direct admission (top) vs. interhospital transfer (bottom). There is a significant difference
between the 2 groups by shift analysis (P=0.012 by CochranMantel-Haenszel test). B, Comparison of outcomes based on
mRS between direct and transfer divided into patients who
received IV-tPA before MT (top) and those who underwent
MT alone (bottom). Shift analysis revealed a significant
difference between transfer and direct groups for MT alone
(P=0.035) and a nonsignificant trend for IV-tPA (P=0.14). IVtPA indicates intravenous tissue plasminogen activator; mRS,
modified Rankin Scale; and MT, mechanical thrombectomy.

sion was used with the outcome of functional independence (mRS 0–2) by time from onset while accounting
for multiple covariates (Table 2). Good outcome was
less likely with increasing age, increasing NIHSS before
treatment, and intracranial internal carotid artery occlusion (versus middle cerebral artery). Increasing time
from onset to treatment was also significantly associated with lower likelihood of good outcome, with an
adjusted OR of 0.93 for every additional 30-minute delay (95% CI, 0.89–0.98; P=0.008). When time to treatment was accounted for, there was no additional effect
of direct presentation versus transfer on functional outcome (adjusted OR, 1.05; 95% CI, 0.76–1.45). Figure 3
displays the effect of time to treatment on outcome
for both direct and transfer patients. Although time to
treatment is systematically longer in the transfer group,
the effect of time on outcome as measured by the slopes
of the 2 response curves is similar (P=0.35, test of in2316
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teraction effect between transfer status and time), supporting the hypothesis that the difference between the
2 groups is solely because of treatment delay. Across all
patients, the absolute rate of functional independence
decreased by 5.5% per hour from alarm to puncture.
Additional univariate analysis showed that successful
reperfusion was also strongly correlated with functional
independence (OR, 2.21; 95% CI, 1.42–3.43).
We performed an additional propensity score analysis to assess the role of all available standard stroke
covariates, including age, qualifying NIHSS, vessel of
target occlusion, tPA administration, ASPECTS score at
baseline, sex, arterial occlusion location, smoking status, history of atrial fibrillation, diabetes mellitus, history of recent stroke, carotid artery stenosis, history of
coronary disease, hyperlipidemia, prestroke functional
status, and hypertension. After further adjustment
for these variables and as seen in the multivariate regression analysis, results after propensity adjustment
indicated a significant effect of time but not transfer
status, as shown in Table 3. Also as before, the interaction between tPA and time was nonsignificant in the
propensity-adjusted models, with P=0.14 for the covariate model and P=0.15 for the stratified model.

Hypothetical Bypass Analysis
A total of 209 patients were transferred via ground
and available for analysis in the hypothetical bypass
scenario. Of these patients, 122 (58.4%) received IVtPA at the first hospital, with a median onset-to-tPA
time of 106 minutes (IQR, 81–136). Using the bypass
model, 116 (95.1%) would still receive IV-tPA (6 no longer met guideline recommendations), and the median
Circulation. 2017;136:2311–2321. DOI: 10.1161/CIRCULATIONAHA.117.028920

Interhospital Transfer Before Thrombectomy

ORIGINAL RESEARCH
ARTICLE
Figure 3. Relationship between rate of functional independence (mRS 0–2 at 90 days) and time from onset to puncture for direct (blue) vs. transfer (red) patients.
The logistic curves have been truncated at the 95% distribution for each group, and thus the transfer group is shifted to the
right (later average treatment time) compared with the direct group. Shading represents the 95% confidence interval for each
group. The slopes do not differ between the 2 groups (P=0.35), suggesting that differences in outcome are related only to
time. The rate of functional independence decreased by 5.5% per hour for all patients. mRS indicates modified Rankin Scale.
Downloaded from http://ahajournals.org by on February 4, 2021

onset-to-tPA time would increase to 123 minutes (IQR,
90–160). The median onset-to-puncture time in all
209 patients was 250 minutes (IQR, 201–330), which
would decrease to 169 minutes (IQR, 133–223) with
hypothetical bypass. When comparing mean times,
tPA would be administered 12.0 minutes later (±SD of
46.9), but endovascular treatment would be delivered
91.0 minutes sooner (±47.6).
A total of 130 patients were transferred despite initially being within 20 miles of the endovascular hospital.
Among these patients, 71 (54.6%) received IV-tPA at the
first hospital, with a median onset-to-tPA of 100 minutes (IQR, 80–130). In the hypothetical bypass model, 69
(97.2%) would still receive IV-tPA (2 excluded by guidelines), and median onset-to-tPA would increase to 102
minutes (IQR, 78–143). Median onset-to-puncture in all
130 patients was 240 minutes (IQR, 190–310), which
would decrease to 148 minutes (IQR, 117–198) with hypothetical bypass. When comparing mean times for the
patients within 20 miles, tPA would be administered 6.9
minutes later (±SD of 44.8), but endovascular treatment
would be delivered 94.0 minutes sooner (±46.4).

associated with mean treatment delays of 116 minutes
compared with direct presentation to the endovascularcapable center. Interhospital transfer was associated
with lower chances of excellent clinical outcome (47.4%
versus 38.0%) and lower chances of functional independence (60.0% versus 52.2%). The difference in rates of
good outcome between the 2 groups was entirely attributable to time delays; when controlling for time from
onset to treatment, there was no difference in outcomes
between direct and transfer patients.
Time delays in the transfer group were mainly attributable to 3 epochs: picture to departure for MT
alone (75 minutes), tPA to departure for tPA+MT (47
minutes), and transfer transport time (35 minutes). The
first 2 time epochs suggest that much of the delay associated with transfer is because of medical decision
making or the logistics of arranging transport. Despite
these delays, other time epochs were actually shorter in
the transfer group (such as picture-to-puncture times at
Table 3. Predictors of mRS 0 to 2 at 90 Days Using
Propensity Score Analysis
Model 1: Propensity
Score as Covariate

Model 2: Propensity
Score as Stratifier

DISCUSSION

Predictor of mRS 0–2

This study provides important information regarding the
impact of systems of care for patients with LVO stroke
undergoing MT. We found that interhospital transfer was

Onset to arterial puncture

0.017

0.013

Transfer vs. direct

0.918

0.964
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the enrolling hospital), presumably because of advance
notice of the patient’s admission.
The relationship between time to treatment and outcomes has been described in several recent studies. The
recent HERMES analysis (Highly Effective Reperfusion
Evaluated in Multiple Endovascular Stroke Trials) reported
a linear reduction in chances of good outcome with increasing time between onset and MT, with no significant
benefit beyond 7.3 hours.10 A subanalysis of the SWIFT
PRIME study (Solitaire FR With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute
Ischemic Stroke) found a high rate of good outcomes for
patients treated with MT within 2.5 hours of onset, but
this rate decreased by 10% over the next hour and by
20% with every subsequent hour of delay.21 In the current study, we found that the rate of good outcome was
reduced by 5.5% for each 1-hour delay from alarm to
puncture. The difference between these 2 studies likely
reflects selection bias: patients enrolled in the randomized study were selected by a strict set of inclusion criteria,
whereas patients in this real-world registry were treated
based on the opinion of the local treatment team. These
treatment decisions were likely based on various factors
predictive of outcome, and patients likely to have a good
outcome despite longer time from onset were probably
still treated. Furthermore, the accelerated reduction in
chance of good outcome after 3.5 hours that was seen
in SWIFT PRIME21 was not observed in the current study.
This difference is also likely attributable to enrollment differences: patients who may have otherwise been eligible
for MT but had imaging signs of established infarction
were likely not treated as they were in SWIFT PRIME.
It is interesting to note that another recent but smaller
registry of MT did not find a significant difference in outcome between direct and transfer patients, despite onset-to-recanalization times of 297 versus 240 minutes.22
However, that study was smaller (159 patients), included
only a single referring center and a single MT center, and
observed a smaller time difference between direct and
transfer patients. Given that we observed a 5.5% reduction in good outcomes for each hour of delay, the results
of this smaller study are not necessarily incongruent and
may reflect circumstances specific to that singular center. Another recent study using a large national database
reported a higher mortality rate associated with transfer
(18.6%) compared with direct presentation (14.9%) for
MT.23 Although our study did not reveal a mortality difference between the 2 groups, the overall mortality rates are
similar between the 2 studies. Given that the database
study included 8533 patients, it is certainly reasonable to
think that a small but significant mortality difference does
exist between direct and transfer patient cohorts.
The administration of IV-tPA did not have a significant impact on outcome in this cohort, and time to MT
remained the most important determinant of outcome.
However, it is important to note that any patient who

successfully achieved thrombolysis with IV-tPA alone
would not undergo MT and would become ineligible
for the current registry. The impact of IV-tPA before
MT was recently explored in a pooled analysis of the
SWIFT and STAR studies (Solitaire FR With the Intention for Thrombectomy and Solitaire FR Thrombectomy
for Acute Revascularization).24 That study showed a
nonsignificant difference in rates of good outcome between patients treated with IV-tPA plus MT versus MT
alone (57.7% versus 47.7%; P=0.10). Again, patients
who responded to tPA before MT would not have been
included. The true benefit of early tPA administration
for LVO before MT can be assessed only with a properly
conducted controlled trial, which is now clearly needed.
Currently, IV-tPA is often cited as the reason for avoiding longer transport to an endovascular-capable center, so
that IV-tPA can be administered sooner at a nearer hospital.25–27 In the current study, analysis of all patients undergoing interhospital transfer by ground ambulance suggested that a direct-to-endovascular bypass would delay
IV-tPA to a modest degree (12 minutes) and 5% would
no longer be eligible for tPA, but the start of endovascular
therapy would be greatly accelerated (91 minutes sooner).
When limiting the hypothetical model only to patients initially within 20 miles of the endovascular center, bypass
becomes even more appealing: tPA is delayed by only 6.9
minutes, only 3% miss the opportunity for tPA, and endovascular treatment starts 94 minutes sooner.
A significant delay to treatment because of interhospital transfer may also create a missed opportunity for MT.
Although such patients would not be captured by the
current registry, Sablot et al28 recently described a series
of LVO patients transferred for MT after receiving IV-tPA
at a nonendovascular center. Of 119 patients transferred,
only 52 (44%) actually underwent MT. Significant treatment delays associated with interhospital transfer were
identified as the primary reason that MT was withheld.
Thus, although bypassing the closer hospital may create
missed opportunities for IV-tPA, interhospital transfer appears to create significant missed opportunities for MT.
As systems of care change to accommodate and optimize acute stroke treatments, the triage and transport
of patients with acute stroke suspected of having LVO
may have a significant impact on the emergency department resources. Currently available clinical scales
for use in the field have high rates of false-positive results, with <50% of suspected patients actually undergoing MT.29 Such an influx of unnecessary emergency
department admissions may create a significant burden
on treatment teams. Clearly, more accurate means of
rapid triage and diagnosis are needed.
In the interest of accelerating time to treatment with
both IV-tPA and MT, one might consider offering endovascular therapy at more hospitals (ie, those that are not
currently endovascular-capable). In fact, a majority of designated Primary Stroke Centers already offer some form
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Conclusions
This large, real-world registry of MT for stroke because
of LVO has shown that interhospital transfer before
endovascular treatment with MT is associated with delays to treatment and a significantly lower chance of
good outcome compared with direct presentation to
the endovascular-capable center. Strategies to facilitate
more rapid identification of LVO and direct routing to
endovascular-capable centers for patients with severe
stroke may help improve outcomes.

SOURCES OF FUNDING
This study was supported by Medtronic.
Circulation. 2017;136:2311–2321. DOI: 10.1161/CIRCULATIONAHA.117.028920

DISCLOSURES
No authors received any payments for work on the submitted manuscript. Dr Froehler serves as a scientific consultant
to Medtronic and Blockade and has received a National Institutes of Health grant. Drs Mueller and Zaidat serve as scientific
consultants regarding trial design and conduct to Medtronic.
The University of California, Regents receives funding for Dr
Saver’s services as a scientific consultant regarding trial design
and conduct to Covidien and Stryker and is an employee of
the University of California, which holds a patent on retriever
devices for stroke. Dr Sultan serves as a scientific consultant
to Medtronic. The University of California, Regents receives
funding for Dr Jahan’s services as a scientific consultant regarding trial design and conduct to Medtronic/Covidien and
is an employee of the University of California, which holds a
patent on retriever devices for stroke. Dr Klucznik is on the
Speakers’ Bureau for Medtronic. Dr Hellinger is on the Speakers’ Bureau for Medtronic and serves as a consultant to Penumbra and Cordis Neurovascular (Johnson and Johnson). Dr
Yavagal has received honoraria from Medtronic and serves
as a scientific consultant to Medtronic and Neuralanalytics,
Inc. Dr Yao serves as a consultant/proctor to Medtronic. Dr
Liebeskind has received a National Institute of Health grant
and serves as a scientific consultant to Stryker and Medtronic.
Drs Abou-Chebl and Hassan have received honoraria from
Medtronic. Dr Baxter is on the Spearkers’ Bureau, has received
honoraria, has ownership interest, and serves as a consultant to Penumbra. Dr Bozorgchami serves as a consultant to
Neuravi. Dr Delgado has received honoraria from Penumbra.
Dr English has received honoraria from Medtronic, Stryker
Neurovascular, and Penumbra. Dr Given is on the Speakers’
Bureau and serves as a consultant to Medtronic. Dr Gupta
serves as a consultant to Medtronic and Stryker Neurovascular. Dr Linfante is on the Speakers’ Bureau for Medtronic
and Stryker and has ownership interest in Three Rivers. Dr
Nogueira serves as a consultant to Medtronic, Stryker Neurovascular, Penumbra, Neuravi, Allm Inc. Dr Schirmer has received honoraria from the American Association of Neurological Surgeons and Toshiba and has ownership interest in
NTI. Dr Siddiqui serves as a consultant to Medtronic, Codman,
Penumbra, Stryker, Microvention, Guidepoint Global Consulting, WL Gore & Associates, Three Rivers, Corindus, Amnis
Therapeutics, CereVasc, Pulsar Vascular, The Stroke Project,
Cerebrotech Medical Systems, Rapid Medical, Neuravi, Silk
Road Medical, Rebound Therapeutics, Claret Medical, Intersocietal Accreditation Commission, and Medical University of
South Carolina and has ownership interest in StimMed, Valor
Medical, Cardinal Health, and Medina Medical Systems. Dr
Taqi serves as a consultant to Stryker Neurovascular.

AUTHORS
Michael T. Froehler, MD, PhD; Jeffrey L. Saver, MD; Osama O.
Zaidat, MD; Reza Jahan, MD; Mohammad Ali Aziz-Sultan,
MD; Richard P. Klucznik, MD; Diogo C. Haussen, MD; Frank
R. Hellinger, Jr., MD, PhD; Dileep R. Yavagal, MD; Tom L. Yao,
MD; David S. Liebeskind, MD; Ashutosh P. Jadhav, MD, PhD;
Rishi Gupta, MD; Ameer E. Hassan, DO; Coleman O. Martin,
MD; Hormozd Bozorgchami, MD; Ritesh Kaushal, MD; Raul
G. Nogueira, MD; Ravi H. Gandhi, MD; Eric C. Peterson, MD;
December 12, 2017

2319

ORIGINAL RESEARCH
ARTICLE

Downloaded from http://ahajournals.org by on February 4, 2021

of endovascular treatment, despite not being designated
as Comprehensive Stroke Centers.30 Conceptually, decentralizing the availability of neurointerventionalists would
improve treatment times. However, others have shown
that mortality after stroke intervention is clearly dependent on volume: 1 study reported mortality of 19.7%
at low-volume, 14.9% at medium-volume, and 9.8%
at high-volume centers (P=0.003).31 Although it is unclear whether these mortality differences are related to
the procedure or perioperative care, some have argued
for transportation of the neurointerventionalist to the patient, rather than the other way around. Hui et al32 reported a single case of LVO stroke where the neurointerventionalist was flown to a nonendovascular Primary Stroke
Center and carried out MT there. Patient outcome and
disposition were not reported, but the case does provide
proof of concept and may justify further investigation.
This study does have several limitations. Some differences between the direct and transfer groups were
observed. Specifically, transferred patients had higher
initial NIHSS, suggesting patients with more severe
strokes were transferred for MT. Aside from stroke severity as assessed by the NIHSS, other selection biases
may have led to greater differences between the groups
that could not be accounted for with regression analysis. In fact, additional confounders, such as time of day
or insurance status, are unknown and unaccounted for
in the current study. Furthermore, transferred patients
were more often treated with tPA, which may be related to earlier presentation at the community hospital.
The ASPECTS on imaging before MT was worse in the
transfer group compared with the direct group, likely a
product of longer delays to treatment in the transferred
patients. Although these differences were accounted
for by multivariate regression, they may still have an
influence on the analysis. Another important limitation
of this study is that patients who experienced successful
recanalization with IV-tPA would be excluded. Finally,
the hypothetical bypass analysis is potentially biased by
unknown variables, such as situational traffic delays.
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